HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1x1 Investor ...

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1x1 Investor ...

Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes Topline data from CATT1 Phase 3 trial on track for second half 2026 HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive thera ...

• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 • Cadisegliatin intellectual property portfolio expanded • Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 _____________________________ vTv Therapeutic ...

[Executive Summary & Corporate Update](index=1&type=section&id=Executive%20Summary%20%26%20Corporate%20Update) vTv Therapeutics presents its Q2 2025 financial results and corporate updates, highlighting the progression of cadisegliatin into Phase 3 trials for Type 1 Diabetes [Introduction and CEO Commentary](index=1&type=section&id=Introduction%20and%20CEO%20Commentary) vTv Therapeutics reported Q2 2025 financial results and provided a corporate update, highlighting the advancement of cadisegliatin into Phase 3 trials for Type 1 Diabetes, which the CEO believes addresses a significant unmet medical need - vTv Therapeutics is a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D)[2](index=2&type=chunk) - The first participant was randomized in the CATT1 Phase 3 trial for cadisegliatin, reflecting continued momentum in its advancement[3](index=3&type=chunk) - Cadisegliatin is designed to selectively activate glucokinase in the liver, aiming to improve glycemic control and reduce hypoglycemia risk when used alongside insulin[3](index=3&type=chunk) [Recent Company Highlights](index=1&type=section&id=Recent%20Company%20Highlights) Key recent developments include the initiation of the Phase 3 CATT1 trial for cadisegliatin, expansion of its intellectual property portfolio, participation in a corporate presentation, and the appointment of a new Chief Financial Officer - First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for T1D in August 2025, with topline data expected in the second half of 2026[5](index=5&type=chunk)[6](index=6&type=chunk) - Patent allowance for a crystalline salt form of cadisegliatin, extending the patent term through 2041[5](index=5&type=chunk)[6](index=6&type=chunk) - Michael Tung, MD, MBA, was appointed as Chief Financial Officer in May 2025, bringing over 20 years of financial management and strategic leadership experience[6](index=6&type=chunk) [Second Quarter 2025 Financial Results](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results) This section details vTv Therapeutics' financial performance for Q2 2025, including cash position, R&D and G&A expenses, net loss, and condensed consolidated balance sheets and statements of operations [Financial Summary](index=2&type=section&id=Financial%20Summary) vTv Therapeutics reported a decrease in cash position, an increase in R&D expenses due to payroll, a slight decrease in G&A expenses, and an increased net loss for Q2 2025 compared to Q2 2024 Cash Position | Metric | June 30, 2025 (in millions) | December 31, 2024 (in millions) | | :----- | :-------------------------- | :------------------------------ | | Cash | $25.9 | $36.7 | Research & Development (R&D) Expenses (Three Months Ended June 30) | Metric | 2025 (in millions) | 2024 (in millions) | | :----- | :----------------- | :----------------- | | R&D Expenses | $4.1 | $3.4 | General & Administrative (G&A) Expenses (Three Months Ended June 30) | Metric | 2025 (in millions) | 2024 (in millions) | | :----- | :----------------- | :----------------- | | G&A Expenses | $3.6 | $3.7 | Net Loss Attributable to vTv Shareholders (Three Months Ended June 30) | Metric | 2025 (in millions) | 2024 (in millions) | | :----- | :----------------- | :----------------- | | Net Loss | $6.0 | $5.2 | | Basic EPS | $0.92 | $0.81 | [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows a decrease in total assets from $38.266 million at December 31, 2024, to $26.448 million at June 30, 2025, primarily driven by a reduction in cash and cash equivalents. Total stockholders' equity also significantly decreased Key Balance Sheet Figures | Metric | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | | :-------------------------------- | :------------------- | :----------------------- | | Cash and cash equivalents | $25,922 | $36,746 | | Total current assets | $26,374 | $38,113 | | Total assets | $26,448 | $38,266 | | Total liabilities | $24,043 | $23,965 | | Total stockholders' equity | $2,405 | $14,301 | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended June 30, 2025, vTv Therapeutics reported no revenue, an operating loss of $7.721 million, and a net loss attributable to shareholders of $6.046 million, an increase from the prior year. The six-month period also showed an increased net loss Statements of Operations (Three Months Ended June 30) | Metric | 2025 (in thousands) | 2024 (in thousands) | | :-------------------------------------------------- | :------------------ | :------------------ | | Revenue | $— | $— | | Research and development | $4,103 | $3,439 | | General and administrative | $3,618 | $3,716 | | Total operating expenses | $7,721 | $7,155 | | Operating loss | $(7,721) | $(7,155) | | Net loss attributable to vTv Therapeutics Inc. | $(6,046) | $(5,180) | | Net loss per share (basic and diluted, in dollars) | $(0.92) | $(0.81) | Statements of Operations (Six Months Ended June 30) | Metric | 2025 (in thousands) | 2024 (in thousands) | | :-------------------------------------------------- | :------------------ | :------------------ | | Revenue | $— | $1,000 | | Research and development | $6,933 | $6,088 | | General and administrative | $7,291 | $7,694 | | Total operating expenses | $14,224 | $13,782 | | Operating loss | $(14,224) | $(12,782) | | Net loss attributable to vTv Therapeutics Inc. | $(11,138) | $(10,045) | | Net loss per share (basic and diluted, in dollars) | $(1.69) | $(1.97) | [Company and Product Information](index=4&type=section&id=Company%20and%20Product%20Information) This section provides an overview of cadisegliatin as a potential first-in-class treatment for Type 1 Diabetes and details vTv Therapeutics' focus as a late-stage biopharmaceutical company [About Cadisegliatin](index=4&type=section&id=About%20Cadisegliatin) Cadisegliatin (TTP399) is an investigational oral, small molecule, liver-selective glucokinase activator being developed as a potential first-in-class adjunctive treatment for Type 1 Diabetes, aiming to improve glycemic control through hepatic glucose uptake and glycogen storage - Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator[12](index=12&type=chunk) - It is being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D)[12](index=12&type=chunk) - Non-clinical studies suggest cadisegliatin, acting selectively on the liver, increases glucokinase activity independently from insulin, supporting improved glycemic control through hepatic glucose uptake and glycogen storage[12](index=12&type=chunk) [About vTv Therapeutics](index=4&type=section&id=About%20vTv%20Therapeutics) vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with cadisegliatin for Type 1 Diabetes leading its clinical pipeline - vTv Therapeutics is a late-stage biopharmaceutical company[14](index=14&type=chunk) - The company focuses on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases[14](index=14&type=chunk) - vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial for the treatment of type 1 diabetes[14](index=14&type=chunk) [Additional Information](index=4&type=section&id=Additional%20Information) This section contains important cautionary statements regarding forward-looking information and provides essential contact details for investor relations and media inquiries [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section contains cautionary statements regarding forward-looking information, emphasizing that actual results may differ materially due to known and unknown risks and uncertainties, and the company undertakes no obligation to update these statements - The release contains forward-looking statements, identifiable by terms such as 'anticipate,' 'believe,' 'could,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would'[15](index=15&type=chunk) - These statements involve known and unknown risks, uncertainties, and other important factors that may cause actual results, performance, or achievements to be materially different from those expressed or implied[15](index=15&type=chunk) - The company undertakes no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of the release, except as required by law[16](index=16&type=chunk) [Investor and Media Contacts](index=6&type=section&id=Investor%20and%20Media%20Contacts) Contact information for investor relations (John Fraunces, LifeSci Advisors, LLC) and media inquiries (Caren Begun, TellMed Strategies) is provided - Investor Contact: John Fraunces, LifeSci Advisors, LLC, 917-355-2395, jfraunces@lifesciadvisors.com[17](index=17&type=chunk) - Media Contact: Caren Begun, TellMed Strategies, 201-396-8551, caren.begun@tmstrat.com[17](index=17&type=chunk)

HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late- stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application directed to compositions of matter of crystalline forms of salts and co-crystal ...

Topline results from CATT1 Phase 3 trial expected in second half of 2026 HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late- stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced the first study participant has been randomized in the Company's CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment to insulin in adults with type 1 diabetes (T1D). Cadisegliatin is ...

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025. Conference details are as follows: H.C. Wainwright “HCW@Home with vTv ...

Core Viewpoint - vTv Therapeutics Inc. has appointed Dr. Michael Tung as Executive Vice President and Chief Financial Officer, which is a strategic move as the company reinitiates its CATT1 Phase 3 trial for cadisegliatin, a potential treatment for type 1 diabetes [1][2] Company Overview - vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for diabetes and other chronic diseases [3] - The company's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, which is being investigated as a potential first-in-class oral glucokinase activator for type 1 diabetes [3][4] Appointment of Dr. Michael Tung - Dr. Tung brings over 20 years of experience in finance, corporate strategy, investor relations, and business development within the biopharmaceutical industry [2] - His previous roles include Chief Financial Officer at AdvanCell Pty Limited and senior positions at FibroGen Inc. and Aclaris Therapeutics [2] - Dr. Tung holds degrees in economics and biology from The George Washington University and an M.D./M.B.A. from Tufts University School of Medicine [2] Cadisegliatin Details - Cadisegliatin (TTP399) is a novel oral small molecule that selectively activates glucokinase in the liver, aimed at improving glycemic control in type 1 diabetes [4] - Non-clinical studies indicate that cadisegliatin increases glucokinase activity independently from insulin, supporting its clinical investigation [4]